DHEA Formulations and methods for treating dry skin
OwnerNorman Orentreichinventor
Life of this patent
Estimating the term…
Abstract
Topical formulations for treating dry skin with dehydroepiandrosterone (DHEA) may contain a keratolytic agent to counteract the formation of acne-like skin lesions without diminishing the effectiveness of DHEA in increasing sebum production. The keratolytic agent may be a hydroxybenzoic acid, alpha-hydroxycarboxylic acid or urea, with salicylic acid being preferred. The DHEA and keratolytic agent may be formulated in a non-toxic, dermatologically acceptable vehicle including tinctures, creams, ointments, gels and lotions.
Claims16
A topical composition for treating dry skin in a patient comprising:
- a. dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof in an amount effective to increase sebum production;
- b. a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectineness of dehydroepiandrosterone or its derivative;
- and
- c. a non-toxic, dermatologically acceptable vehicle.
A method of treating dry skin in a patient which comprises topically administering to the area of dry skin in the patient a composition comprising (a) an effective amount of dehydroepiandrosterone and/or a pharmaceutically acceptable, therapeutically effective derivative thereof and (b) a keratolytic agent in an amount sufficient to counteract the formation of acne-like skin lesions without diminishing the effectiveness of dehydroepiandrosterone or its derivative.
Dependencies are inferred from the claim text.